{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:37:37Z","timestamp":1793342257158,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["K12CA090628"],"award-info":[{"award-number":["K12CA090628"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R37CA266344-01"],"award-info":[{"award-number":["R37CA266344-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CA201127"],"award-info":[{"award-number":["CA201127"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-51978-3","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T18:03:50Z","timestamp":1726509830000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["IL-4 drives exhaustion of CD8+ CART cells"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2288-2230","authenticated-orcid":false,"given":"Carli M.","family":"Stewart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth L.","family":"Siegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0293-5577","authenticated-orcid":false,"given":"R. Leo","family":"Sakemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2984-0834","authenticated-orcid":false,"given":"Michelle J.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7521-4185","authenticated-orcid":false,"given":"Truc","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3308-2704","authenticated-orcid":false,"given":"Brooke","family":"Kimball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0569-5326","authenticated-orcid":false,"given":"Ismail","family":"Can","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Manriquez Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2782-8527","authenticated-orcid":false,"given":"Kun","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0634-407X","authenticated-orcid":false,"given":"Olivia","family":"Sirpilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Girsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekene","family":"Ogbodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1782-7296","authenticated-orcid":false,"given":"Wazim","family":"Mohammed Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8528-5575","authenticated-orcid":false,"given":"Alexandre","family":"Gaspar-Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Budka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3743-7102","authenticated-orcid":false,"given":"Nathalie","family":"Scholler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Mattie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Filosto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2767-3830","authenticated-orcid":false,"given":"Saad S.","family":"Kenderian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"key":"51978_CR1","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1080\/10428194.2021.1894648","volume":"62","author":"R Sakemura","year":"2021","unstructured":"Sakemura, R., Cox, M. J., Hefazi, M., Siegler, E. L. & Kenderian, S. S. Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies. Leuk Lymphoma 62, 2052\u20132063 (2021).","journal-title":"Leuk Lymphoma"},{"key":"51978_CR2","unstructured":"Neelapu, S. S. et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 141, 2307\u20132315 (2023)."},{"key":"51978_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 20, 31\u201342 (2019).","journal-title":"Lancet Oncol."},{"key":"51978_CR4","doi-asserted-by":"crossref","unstructured":"Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. 380, 45\u201356 (2018).","DOI":"10.1056\/NEJMoa1804980"},{"key":"51978_CR5","doi-asserted-by":"crossref","unstructured":"Wittibschlager, V. et al. CAR T-cell persistence correlates with improved outcome in patients with B-cell lymphoma. Int. J. Mol. Sci. 24, 5688 (2023).","DOI":"10.3390\/ijms24065688"},{"key":"51978_CR6","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah, N. N. & Fry, T. J. Mechanisms of resistance to CAR T cell therapy. Nat. Rev. Clin. Oncol. 16, 372\u2013385 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"51978_CR7","doi-asserted-by":"publisher","first-page":"110079","DOI":"10.1016\/j.celrep.2021.110079","volume":"37","author":"CC Zebley","year":"2021","unstructured":"Zebley, C. C. et al. CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia. Cell Rep. 37, 110079 (2021).","journal-title":"Cell Rep."},{"key":"51978_CR8","doi-asserted-by":"crossref","unstructured":"Beider, K. et al. Molecular and functional signatures associated with CAR T cell exhaustion and impaired clinical response in patients with B cell malignancies. Cells 11, 1140 (2022).","DOI":"10.3390\/cells11071140"},{"key":"51978_CR9","first-page":"492","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry, E. J. T cell exhaustion 12, 492\u2013499 (2011).","journal-title":"T cell exhaustion"},{"key":"51978_CR10","doi-asserted-by":"publisher","first-page":"eaba1786","DOI":"10.1126\/science.aba1786","volume":"372","author":"EW Weber","year":"2021","unstructured":"Weber, E. W. et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science 372, eaba1786 (2021).","journal-title":"Science"},{"key":"51978_CR11","doi-asserted-by":"publisher","first-page":"eabh0272","DOI":"10.1126\/scitranslmed.abh0272","volume":"13","author":"B Prinzing","year":"2021","unstructured":"Prinzing, B. et al. Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Sci. Transl. Med. 13, eabh0272 (2021).","journal-title":"Sci. Transl. Med."},{"key":"51978_CR12","doi-asserted-by":"crossref","unstructured":"Yu, B. et al. Epigenetic landscapes reveal transcription factors that regulate CD8+ T cell differentiation. Nat. Immunol. 18, 573-582 (2017).","DOI":"10.1038\/ni.3706"},{"key":"51978_CR13","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/imm.13575","volume":"167","author":"F Li","year":"2022","unstructured":"Li, F., Liu, H., Zhang, D., Ma, Y. & Zhu, B. Metabolic plasticity and regulation of T cell exhaustion. Immunology 167, 482\u2013494 (2022).","journal-title":"Immunology"},{"key":"51978_CR14","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","volume":"52","author":"J-C Beltra","year":"2020","unstructured":"Beltra, J.-C. et al. Developmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity. 52, 825\u2013841 (2020).","journal-title":"Immunity."},{"key":"51978_CR15","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","volume":"567","author":"J Chen","year":"2019","unstructured":"Chen, J. et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature 567, 530\u2013534 (2019).","journal-title":"Nature"},{"key":"51978_CR16","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.immuni.2019.09.013","volume":"51","author":"Z Chen","year":"2019","unstructured":"Chen, Z. et al. TCF-1-centered transcriptional network drives an effector versus exhausted CD8 T cell-fate decision. Immunity 51, 840\u2013855.e845 (2019).","journal-title":"Immunity"},{"key":"51978_CR17","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature11530","volume":"490","author":"P Li","year":"2012","unstructured":"Li, P. et al. BATF\u2013JUN is critical for IRF4-mediated transcription in T cells. Nature. 490, 543\u2013546 (2012).","journal-title":"Nature."},{"key":"51978_CR18","doi-asserted-by":"publisher","first-page":"109120","DOI":"10.1016\/j.celrep.2021.109120","volume":"35","author":"LM McLane","year":"2021","unstructured":"McLane, L. M. et al. Role of nuclear localization in the regulation and function of T-bet and Eomes in exhausted CD8 T cells. Cell Rep. 35, 109120 (2021).","journal-title":"Cell Rep."},{"key":"51978_CR19","doi-asserted-by":"publisher","first-page":"12410","DOI":"10.1073\/pnas.1905675116","volume":"116","author":"H Seo","year":"2019","unstructured":"Seo, H. et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion. Proc Natl Acad Sci USA. 116, 12410\u201312415 (2019).","journal-title":"Proc Natl Acad Sci USA."},{"key":"51978_CR20","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41590-021-00964-8","volume":"22","author":"H Seo","year":"2021","unstructured":"Seo, H. et al. BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. Nat. Immunol. 22, 983\u2013995 (2021).","journal-title":"Nat. Immunol."},{"key":"51978_CR21","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1158\/2326-6066.CIR-18-0664","volume":"7","author":"B Yigit","year":"2019","unstructured":"Yigit, B. et al. SLAMF6 as a regulator of exhausted CD8+ T cells in cancer. Cancer Immunol Res. 7, 1485\u20131496 (2019).","journal-title":"Cancer Immunol Res."},{"key":"51978_CR22","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.3389\/fimmu.2018.02981","volume":"9","author":"J Li","year":"2018","unstructured":"Li, J., He, Y., Hao, J., Ni, L. & Dong, C. High levels of eomes promote exhaustion of anti-tumor CD8(+) T cells. Front. Immunol. 9, 2981 (2018).","journal-title":"Front. Immunol."},{"key":"51978_CR23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.immuni.2009.06.019","volume":"31","author":"H Shin","year":"2009","unstructured":"Shin, H. et al. A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection. Immunity 31, 309\u2013320 (2009).","journal-title":"Immunity"},{"key":"51978_CR24","doi-asserted-by":"crossref","unstructured":"Jung, I. Y. et al. Type I Interferon signaling via the EGR2 transcriptional regulator potentiates CAR T cell-intrinsic dysfunction. Cancer Discov. 13, 1636\u20131655 (2023).","DOI":"10.1158\/2159-8290.CD-22-1175"},{"key":"51978_CR25","doi-asserted-by":"publisher","first-page":"eabn7336","DOI":"10.1126\/scitranslmed.abn7336","volume":"14","author":"IY Jung","year":"2022","unstructured":"Jung, I. Y. et al. BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion. Sci .Transl. Med. 14, eabn7336 (2022).","journal-title":"Sci .Transl. Med."},{"key":"51978_CR26","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.ccell.2022.09.013","volume":"40","author":"X Zhang","year":"2022","unstructured":"Zhang, X. et al. Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells. Cancer Cell 40, 1407\u20131422 e1407 (2022).","journal-title":"Cancer Cell"},{"key":"51978_CR27","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature. 576, 293\u2013300 (2019).","journal-title":"Nature."},{"key":"51978_CR28","doi-asserted-by":"publisher","first-page":"e2218632120","DOI":"10.1073\/pnas.2218632120","volume":"120","author":"D Mai","year":"2023","unstructured":"Mai, D. et al. Combined disruption of T cell inflammatory regulators Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T cells. Proc Natl Acad Sci USA 120, e2218632120 (2023).","journal-title":"Proc Natl Acad Sci USA"},{"key":"51978_CR29","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581\u2013590 (2015).","journal-title":"Nat. Med."},{"key":"51978_CR30","doi-asserted-by":"crossref","unstructured":"Harush, O. et al. Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma. Haematologica, 107, 2395\u20132407 (2022).","DOI":"10.3324\/haematol.2021.280169"},{"key":"51978_CR31","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","volume":"20","author":"AJ Hou","year":"2021","unstructured":"Hou, A. J., Chen, L. C. & Chen, Y. Y. Navigating CAR-T cells through the solid-tumour microenvironment. Nat. Rev. Drug Discov. 20, 531\u2013550 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"51978_CR32","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"51978_CR33","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.ccell.2022.06.001","volume":"40","author":"JA Belk","year":"2022","unstructured":"Belk, J. A. et al. Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence. Cancer Cell 40, 768\u2013786.e767 (2022).","journal-title":"Cancer Cell"},{"key":"51978_CR34","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nmeth.3047","volume":"11","author":"NE Sanjana","year":"2014","unstructured":"Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783\u2013784 (2014).","journal-title":"Nat. Methods"},{"key":"51978_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-015-0843-6","volume":"16","author":"W Li","year":"2015","unstructured":"Li, W. et al. Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR. Genome Biol. 16, 281 (2015).","journal-title":"Genome Biol."},{"key":"51978_CR36","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1038\/s41375-022-01572-7","volume":"36","author":"MJ Cox","year":"2022","unstructured":"Cox, M. J. et al. GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity. Leukemia 36, 1635\u20131645 (2022).","journal-title":"Leukemia"},{"key":"51978_CR37","doi-asserted-by":"publisher","first-page":"eabe8219","DOI":"10.1126\/sciimmunol.abe8219","volume":"6","author":"A Sutra Del Galy","year":"2021","unstructured":"Sutra Del Galy, A. et al. In vivo genome-wide CRISPR screens identify SOCS1 as intrinsic checkpoint of CD4(+) T(H)1 cell response. Sci. Immunol. 6, eabe8219 (2021).","journal-title":"Sci. Immunol."},{"key":"51978_CR38","doi-asserted-by":"publisher","first-page":"e103637","DOI":"10.15252\/embj.2019103637","volume":"39","author":"F Wiede","year":"2020","unstructured":"Wiede, F. et al. PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours. EMBO J 39, e103637 (2020).","journal-title":"EMBO J"},{"key":"51978_CR39","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/s41590-019-0480-4","volume":"20","author":"MW LaFleur","year":"2019","unstructured":"LaFleur, M. W. et al. PTPN2 regulates the generation of exhausted CD8(+) T cell subpopulations and restrains tumor immunity. Nat. Immunol. 20, 1335\u20131347 (2019).","journal-title":"Nat. Immunol."},{"key":"51978_CR40","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41590-020-00850-9","volume":"22","author":"Y Liu","year":"2021","unstructured":"Liu, Y. et al. IL-2 regulates tumor-reactive CD8(+) T cell exhaustion by activating the aryl hydrocarbon receptor. Nat. Immunol. 22, 358\u2013369 (2021).","journal-title":"Nat. Immunol."},{"key":"51978_CR41","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.3389\/fimmu.2019.02832","volume":"10","author":"HM Parry","year":"2019","unstructured":"Parry, H. M. et al. Long-term ibrutinib therapy reverses CD8(+) T cell exhaustion in b cell chronic lymphocytic leukaemia. Front. Immunol. 10, 2832 (2019).","journal-title":"Front. Immunol."},{"key":"51978_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03626-x","volume":"20","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy. J. Transl. Med. 20, 432 (2022).","journal-title":"J. Transl. Med."},{"key":"51978_CR43","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.4049\/jimmunol.162.7.4285","volume":"162","author":"T Jinquan","year":"1999","unstructured":"Jinquan, T., Quan, S., Feili, G., Larsen, C. G. & Thestrup-Pedersen, K. Eotaxin activates T cells to chemotaxis and adhesion only if induced to express CCR3 by IL-2 together with IL-4. J. Immunol. 162, 4285\u20134292 (1999).","journal-title":"J. Immunol."},{"key":"51978_CR44","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/ni.1966","volume":"12","author":"S Tanaka","year":"2011","unstructured":"Tanaka, S. et al. The enhancer HS2 critically regulates GATA-3-mediated Il4 transcription in T(H)2 cells. Nat. Immunol. 12, 77\u201385 (2011).","journal-title":"Nat. Immunol."},{"key":"51978_CR45","doi-asserted-by":"publisher","first-page":"e106659","DOI":"10.1371\/journal.pone.0106659","volume":"9","author":"SA Carty","year":"2014","unstructured":"Carty, S. A., Koretzky, G. A. & Jordan, M. S. Interleukin-4 regulates eomesodermin in CD8+ T cell development and differentiation. PLoS ONE 9, e106659 (2014).","journal-title":"PLoS ONE"},{"key":"51978_CR46","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3322\/caac.21771","volume":"73","author":"RH Parikh","year":"2023","unstructured":"Parikh, R. H. & Lonial, S. Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice. CA Cancer J. Clin. 73, 275\u2013285 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"51978_CR47","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726\u20131737 (2019).","journal-title":"N. Engl. J. Med."},{"key":"51978_CR48","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1182\/blood.2021012811","volume":"139","author":"R Sakemura","year":"2022","unstructured":"Sakemura, R. et al. Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma. Blood 139, 3708\u20133721 (2022).","journal-title":"Blood"},{"key":"51978_CR49","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","volume":"133","author":"RM Sterner","year":"2019","unstructured":"Sterner, R. M. et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood 133, 697\u2013709 (2019).","journal-title":"Blood"},{"key":"51978_CR50","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000447692","volume":"170","author":"D Bagnasco","year":"2016","unstructured":"Bagnasco, D., Ferrando, M., Varricchi, G., Passalacqua, G. & Canonica, G. W. A critical evaluation of anti-il-13 and anti-il-4 strategies in severe asthma. Int. Arch. Allergy Immunol. 170, 122\u2013131 (2016).","journal-title":"Int. Arch. Allergy Immunol."},{"key":"51978_CR51","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1080\/21645515.2019.1582403","volume":"15","author":"Q Thibodeaux","year":"2019","unstructured":"Thibodeaux, Q. et al. A review of dupilumab in the treatment of atopic diseases. Hum. Vaccin. Immunother. 15, 2129\u20132139 (2019).","journal-title":"Hum. Vaccin. Immunother."},{"key":"51978_CR52","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jaci.2012.03.030","volume":"130","author":"RE Slager","year":"2012","unstructured":"Slager, R. E. et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist. J. Allergy Clin. Immunol. 130, 516\u2013522.e514 (2012).","journal-title":"J. Allergy Clin. Immunol."},{"key":"51978_CR53","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s12551-013-0133-z","volume":"6","author":"JL Silva-Filho","year":"2014","unstructured":"Silva-Filho, J. L., Caruso-Neves, C. & Pinheiro, A. A. S. IL-4: an important cytokine in determining the fate of T cells. Biophys. Rev. 6, 111\u2013118 (2014).","journal-title":"Biophys. Rev."},{"key":"51978_CR54","doi-asserted-by":"publisher","first-page":"eabj2820","DOI":"10.1126\/sciadv.abj2820","volume":"8","author":"Z Bai","year":"2022","unstructured":"Bai, Z. et al. Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. Sci. Adv. 8, eabj2820 (2022).","journal-title":"Sci. Adv."},{"key":"51978_CR55","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1158\/2326-6066.CIR-23-0577","volume":"11","author":"TS Nowicki","year":"2023","unstructured":"Nowicki, T. S. et al. Infusion product TNFalpha, Th2, and STAT3 activities are associated with clinical responses to transgenic T-Cell Receptor Cell therapy. Cancer Immunol. Res. 11, 1589\u20131597 (2023).","journal-title":"Cancer Immunol. Res."},{"key":"51978_CR56","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood-2019-123277","volume":"134","author":"R Sakemura","year":"2019","unstructured":"Sakemura, R. et al. Targeting cancer associated fibroblasts in the bone marrow prevents resistance to chimeric antigen receptor T cell therapy in multiple myeloma. Blood 134, 865\u2013865 (2019).","journal-title":"Blood"},{"key":"51978_CR57","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00262-017-2043-6","volume":"66","author":"SE Ito","year":"2017","unstructured":"Ito, S. E., Shirota, H., Kasahara, Y., Saijo, K. & Ishioka, C. IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model. Cancer Immunol. Immunother. 66, 1485\u20131496 (2017).","journal-title":"Cancer Immunol. Immunother."},{"key":"51978_CR58","doi-asserted-by":"publisher","first-page":"205031212110690","DOI":"10.1177\/20503121211069012","volume":"10","author":"B Mirlekar","year":"2022","unstructured":"Mirlekar, B. Tumor promoting roles of IL-10, TGF-beta, IL-4, and IL-35: Its implications in cancer immunotherapy. SAGE Open Med. 10, 20503121211069012 (2022).","journal-title":"SAGE Open Med."},{"key":"51978_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13608-1","volume":"10","author":"W Cai","year":"2019","unstructured":"Cai, W. et al. PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growth. Nat. Commun. 10, 5800 (2019).","journal-title":"Nat. Commun."},{"key":"51978_CR60","doi-asserted-by":"publisher","first-page":"eabb3420","DOI":"10.1126\/science.abb3420","volume":"374","author":"I Sturmlechner","year":"2021","unstructured":"Sturmlechner, I. et al. p21 produces a bioactive secretome that places stressed cells under immunosurveillance. Science 374, eabb3420 (2021).","journal-title":"Science"},{"key":"51978_CR61","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"51978_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"51978_CR63","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1093\/bioinformatics\/btac166","volume":"38","author":"GH Putri","year":"2022","unstructured":"Putri, G. H., Anders, S., Pyl, P. T., Pimanda, J. E. & Zanini, F. Analysing high-throughput sequencing data in Python with HTSeq 2.0. Bioinformatics 38, 2943\u20132945 (2022).","journal-title":"Bioinformatics"},{"key":"51978_CR64","unstructured":"Blighe, K., Rana, S. & Lewis, M. EnhancedVolcano: Publication-Ready Volcano Plots with Enhanced Colouring and Labeling https:\/\/github.com\/kevinblighe\/EnhancedVolcano (2021)."},{"key":"51978_CR65","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","volume":"30","author":"A Kramer","year":"2014","unstructured":"Kramer, A., Green, J., Pollard, J. Jr. & Tugendreich, S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 30, 523\u2013530 (2014).","journal-title":"Bioinformatics"},{"key":"51978_CR66","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1093\/bioinformatics\/btv145","volume":"31","author":"G Yu","year":"2015","unstructured":"Yu, G., Wang, L. G. & He, Q. Y. ChIPseeker: an R\/Bioconductor package for ChIP peak annotation, comparison and visualization. Bioinformatics 31, 2382\u20132383 (2015).","journal-title":"Bioinformatics"},{"key":"51978_CR67","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nprot.2017.016","volume":"12","author":"J Joung","year":"2017","unstructured":"Joung, J. et al. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. Nat Protoc. 12, 828\u2013863 (2017).","journal-title":"Nat Protoc."},{"key":"51978_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-015-0843-6","volume":"16","author":"W Li","year":"2015","unstructured":"Li, W. et al. Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR. Genome Biol. 16, 1\u201313 (2015).","journal-title":"Genome Biol."},{"key":"51978_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14, 128 (2013).","journal-title":"BMC Bioinformatics"},{"key":"51978_CR70","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1002\/cpz1.90","volume":"1","author":"Z Xie","year":"2021","unstructured":"Xie, Z. et al. Gene set knowledge discovery with Enrichr. Curr Protoc 1, e90 (2021).","journal-title":"Curr Protoc"},{"key":"51978_CR71","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51978-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51978-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51978-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T10:44:12Z","timestamp":1726742652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51978-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["51978"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-51978-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]},"assertion":[{"value":"14 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.S.K. is an inventor on patents in the field of CAR immunotherapy that are licensed to Novartis (through an agreement between Mayo Clinic, University of Pennsylvania, and Novartis). R.L.S., M.J.C., and S.S.K. are inventors on patents in the field of CAR immunotherapy that are licensed to Humanigen (through Mayo Clinic). S.S.K. is an inventor on patents in the field of CAR immunotherapy that are licensed to Mettaforge (through Mayo Clinic). S.S.K. receives research funding from Kite, Gilead, Juno, BMS, Novartis, Humanigen, MorphoSys, Tolero, Sunesis\/Viracta, LifEngine Animal Health Laboratories Inc, and Lentigen. S.S.K. has participated in advisory meetings with Kite\/Gilead, Calibr, Luminary Therapeutics, Humanigen, Juno\/BMS, Capstan Bio, and Novartis. SSK has served on the data safety and monitoring board with Humanigen. S.S.K. has severed a consultant for Torque, Calibr, Novartis, Capstan Bio, and Humanigen. J.B., J.K., M.M., N.S., and S.F. are employed by Gilead. C.M.S., M.M., S.F., and S.S.K. are inventors on intellectual property related to this work. All other authors do not have competing interests to disclose at this time.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7921"}}